Focused On-demand Library for tRNA-dihydrouridine(47) synthase [NAD(P)(+)]-like

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

mRNA-dihydrouridine synthase DUS3L; tRNA-dihydrouridine synthase 3-like

Alternative UPACC:

Q96G46; Q96HM5; Q9BSU4; Q9H877; Q9NPR1


The tRNA-dihydrouridine(47) synthase [NAD(P)(+)]-like, also known as mRNA-dihydrouridine synthase DUS3L and tRNA-dihydrouridine synthase 3-like, plays a crucial role in RNA modification. It catalyzes the synthesis of dihydrouridine in various RNAs, including tRNAs, mRNAs, and lncRNAs, primarily modifying the uridine at position 47 in the D-loop of most cytoplasmic tRNAs. This modification process is vital for the proper functioning of these RNAs.

Therapeutic significance:

Understanding the role of tRNA-dihydrouridine(47) synthase [NAD(P)(+)]-like could open doors to potential therapeutic strategies. Its involvement in the modification of RNAs highlights its importance in cellular processes and its potential as a target for drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.